Barclays Reiterates “$40.00” Price Target for Revance Therapeutics (NASDAQ:RVNC)

Barclays set a $40.00 price objective on Revance Therapeutics (NASDAQ:RVNC) in a research report released on Tuesday, December 19th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

RVNC has been the subject of several other reports. Piper Jaffray Companies reiterated a buy rating and set a $28.00 target price on shares of Revance Therapeutics in a report on Friday, October 27th. Zacks Investment Research upgraded shares of Revance Therapeutics from a hold rating to a buy rating and set a $28.00 price objective for the company in a report on Friday, September 8th. Cantor Fitzgerald set a $50.00 price objective on shares of Revance Therapeutics and gave the stock a buy rating in a report on Tuesday, October 24th. SunTrust Banks boosted their price objective on shares of Revance Therapeutics to $53.00 and gave the stock a buy rating in a report on Friday, December 8th. Finally, Guggenheim started coverage on shares of Revance Therapeutics in a report on Tuesday, December 5th. They issued a buy rating and a $42.00 price objective for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $43.11.

Revance Therapeutics (NASDAQ RVNC) traded up $0.15 during trading on Tuesday, reaching $33.95. The company’s stock had a trading volume of 397,141 shares, compared to its average volume of 490,855. The company has a market cap of $1,050.00, a PE ratio of -8.91 and a beta of 1.62. Revance Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $37.45.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.05 million. During the same quarter in the previous year, the business posted ($0.64) earnings per share. Revance Therapeutics’s revenue for the quarter was up .0% on a year-over-year basis. research analysts forecast that Revance Therapeutics will post -3.73 earnings per share for the current fiscal year.

In other Revance Therapeutics news, CEO L Daniel Browne sold 7,662 shares of the business’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $26.16, for a total transaction of $200,437.92. Following the completion of the sale, the chief executive officer now directly owns 140,788 shares in the company, valued at approximately $3,683,014.08. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Mark J. Foley bought 20,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The shares were bought at an average price of $26.96 per share, with a total value of $539,200.00. Following the completion of the purchase, the director now owns 6,000 shares in the company, valued at approximately $161,760. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 25,262 shares of company stock valued at $658,282. Company insiders own 18.86% of the company’s stock.

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in shares of Revance Therapeutics by 4.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,626,603 shares of the biopharmaceutical company’s stock valued at $95,743,000 after acquiring an additional 166,759 shares during the period. Vanguard Group Inc. grew its position in shares of Revance Therapeutics by 7.3% during the 2nd quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock valued at $24,595,000 after acquiring an additional 63,505 shares during the period. QS Investors LLC bought a new stake in shares of Revance Therapeutics during the 2nd quarter valued at $1,564,000. Northern Trust Corp grew its position in shares of Revance Therapeutics by 19.9% during the 2nd quarter. Northern Trust Corp now owns 318,877 shares of the biopharmaceutical company’s stock valued at $8,418,000 after acquiring an additional 52,940 shares during the period. Finally, Voya Investment Management LLC bought a new stake in shares of Revance Therapeutics during the 2nd quarter valued at $274,000. 76.69% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/revance-therapeutics-rvnc-given-a-40-00-price-target-at-barclays.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply